Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin with FOLFIRI in Metastatic Colorectal Cancer
NCT06826092Phase 2Recruiting
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Start
- Oct 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of metformin in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital. Primary endpoint: Progression-Free Survival up to 52 months. Started Oct 2022; status: recruiting.
02
Drugs
metformin
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06826092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06826092.